A method for personalized optimization of therapy for a patient based on genomic information of the patient and adverse event data of combination therapies, comprising: receiving, by an analyzer executed by a processor of computing device from a user, an identification of a genomic variant resulting in a patient's altered activity of a first protein and an identification of a second medication targeting a second protein to be prescribed to the patient; identifying, by querying a medication information database, responsive to the identification of the genomic variant, a first medication targeting the first protein, wherein the activity of the first protein being altered by the genomic variant is equivalent to a normal patient consuming the first medication; identifying a likelihood of an adverse event occurring through co-medication of the first medication and the second medication by querying an adverse event database for a rate of adverse event records including identification of co-medication of the first medication and the second medication; and identifying the rate as being above a predetermined threshold or below a predetermined threshold; determining that an adverse event is likely to occur if the patient is prescribed the second medication, responsive to the identified likelihood of an adverse event occurring through co-medication of the first medication and the second medication and determining the second medication as contraindicated for the patient, responsive to the patient having the genomic variant or determining that an adverse event is not likely to occur if the patient is prescribed the second medication, responsive to the identified likelihood of an adverse event occurring through co-medication of the first medication and the second medication and determining the second medication as indicated for the patient, responsive to the patient having the genomic variant; and displaying, by a display module executed by computing device, the second medication as contraindicated for the patient having the genomic variant, responsive to the determination that an adverse event is likely to occur, or displaying, by a display module executed by computing device, the second medication as indicated for the patient having the genomic variant, responsive to the determination that an adverse event is not likely to occur. receiving, by an analyzer executed by a processor of computing device from a user, an identification of a genomic variant resulting in a patient's altered activity of a first protein and an identification of a second medication targeting a second protein to be prescribed to the patient; identifying, by querying a medication information database, responsive to the identification of the genomic variant, a first medication targeting the first protein, wherein the activity of the first protein being altered by the genomic variant is equivalent to a normal patient consuming the first medication; identifying a likelihood of an adverse event occurring through co-medication of the first medication and the second medication by querying an adverse event database for a rate of adverse event records including identification of co-medication of the first medication and the second medication; and identifying the rate as being above a predetermined threshold or below a predetermined threshold; determining that an adverse event is likely to occur if the patient is prescribed the second medication, responsive to the identified likelihood of an adverse event occurring through co-medication of the first medication and the second medication and determining the second medication as contraindicated for the patient, responsive to the patient having the genomic variant or determining that an adverse event is not likely to occur if the patient is prescribed the second medication, responsive to the identified likelihood of an adverse event occurring through co-medication of the first medication and the second medication and determining the second medication as indicated for the patient, responsive to the patient having the genomic variant; and displaying, by a display module executed by computing device, the second medication as contraindicated for the patient having the genomic variant, responsive to the determination that an adverse event is likely to occur, or displaying, by a display module executed by computing device, the second medication as indicated for the patient having the genomic variant, responsive to the determination that an adverse event is not likely to occur.